Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma

1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible newly diagnosed multiple myeloma patients. 2. Newly diagnosed multiple myeloma patients treated with daratumumab alongside VRd and lenalidomide maintenance therapy showed higher complete response and minimal residual disease (MRD-negative) rates. Evidence Rating Level: 1 (Excellent) […]

The post Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma first appeared on 2 Minute Medicine.